Skip to content
Fast Company Executive Board

The Fast Company Executive Board is a private, fee-based network of influential leaders, experts, executives, and entrepreneurs who share their insights with our audience.

Profile photo of Shane J. Schaffer

Shane J. Schaffer

Chairman and CEO, Cingulate Inc (NASDAQ: CING)

Shane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and has served as CEO since its inception. Dr. Schaffer is a 25-year pharmaceutical industry veteran with experience in pharmaceutical drug development, commercialization and biotech commercial operations. During his career, he has held positions at Pfizer, Novartis and Sanofi (including predecessor companies). Dr. Schaffer has broad functional and therapeutic expertise through the development and commercialization of several billion dollar brands including the ADHD Franchise of Ritalin® & Focalin®, Lipitor®, Lyrica®, Eligard®, Arixtra®, Hyalgan® and Avapro®/Avalide®. He has led the strategic brand planning, franchise resource allocation and managed care & reimbursement strategy for numerous products. Dr. Schaffer received his Doctor of Pharmacy degree from the University of Kansas. He served as Chief Fellow and completed a Post-Doctoral Pharmaceutical Industry Fellowship at Rutgers University, College of Pharmacy in conjunction with Warner-Lambert/Parke-Davis, now Pfizer.

LOCATION

Kansas City, KS, USA

COMPANY

Cingulate Inc. (NASDAQ: CING) is a biopharmaceutical company leveraging its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to develop and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients with commonly diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. Initially focused on the treatment of ADHD, Cingulate is also evaluating additional therapeutic areas where its PTR™ technology has the potential to improve treatment, including anxiety disorders. Cingulate's lead product candidate, CTx-1301 (dexmethylphenidate HCl), is being evaluated for the treatment of ADHD under the FDA's 505(b)(2) regulatory pathway.